INTRODUCTION
The selective action that steroid hormones and the hormones for the other nuclear receptors have in different tissues and on different responses is well known. In fact, this recognized selectivity forms the basis for major efforts, currently underway in the pharmaceutical industry and at universities, toward the development of new, synthetic hormones whose profile of desired activities is optimized for specific therapeutic and preventative applications. This commentary will examine the pharmacological mechanisms that underlie this selectivity.
The study of steroid hormone pharmacology poses particular challenges. In viva, many steroids have pleiotropic activity, displaying a variety of effects in different tissues. Even in cell-based in vitro systems, attempts to investigate the molecular basis for steroid hormone action and the selectivity of this action are confounded by the fact that the genomic responses elicited by these ligands can be both primary and secondary (Le. cascade) responses. In the latter situation, the correlation between molecular interaction and response is complex and indirect; this makes it difficult to clearly determine what interactions define the pharmacological parameters of potency and bio-0888-8809/96/$3.00/O Molecular Endocrinology Copyright 0 1996 by The Endocrine Society character (biological character, i.e. agonist vs. antagonist activity) of a specific hormone. Even the genomic actions vary: most involve direct receptor-DNA interaction, but some appear to be mediated via interaction of receptor with other DNA-binding proteins. Steroid hormones may also exert nongenomic effects, some of which may still involve the receptor. In this commentary, we are focusing on the genomic action of steroid hormones that involves the regulation of gene transcription mediated by nuclear receptors.
THREE MECHANISMS FOR STEROID HORMONE SELECTIVITY
The selectivity that steroid and other hormones for nuclear receptors display at three different levels-the tissue, the cell, and the gene-may be mediated by three distinct mechanisms (Table 1) : 1) ligand-based selectivity, 2) receptor-based selectivity, and 3) effector site-based selectivity. Since the first two mechanisms are well recognized, they will be described only briefly; the third mechanism merits careful examination and will be discussed in greater detail. experience different interactions at different effector sites regulating gene transcription or differential ligand metabolism. The same hormone or set of hormones is presented to different target tissues through the circulation, but their relative amounts within the cell are altered by differential uptake or metabolism-at the level of the target tissue cell. The differential metabolism mechanism may involve either a bioactivation, such as the tissue-selective conversion of the naturally circulating androgen testosterone to the more potent %-dihydrotestosterone by the action of Sa-reductase (1) or a bioinactivation, such as the selective oxidation of cortisol, but not aldosterone, by an 11 P-dehydrogenase found in tissues that respond to mineralocorticoids (2). Thus, this differential metabolism creates a ligand-based selectivity in which the same receptor in different target tissues or cells can experience a different complexion of hormones and thereby mediate responses in a selective manner (cf. Table 1) .
gen-responsive cells where full length estrogen receptor and splice variants may coexist (14) (15) (16) (17) (18) . In theje systems, the same hormone or set of hormones COI Ild effect tissue-or cell-selective action as a result of 1 ie different complexion of receptors present in different target sites (cf. Table 1 ).
Effector Site-Based Selectivity
Receptor-Based Selectivity
Although the former two mechanisms may explain some of the tissue-and cell-selective actions of steroid and related hormones, the selectivity of these hormones clearly also derives from a deeper level. Even in cases where there seems to be no differential hormone metabolism in target tissues and only a single receptor is involved (i. (53, 54) . Interestingly, the nucleotide sequences comprising the estrogen response elements in these two genes (TGFP3 and vitellogenin) are quite different, vitellogenin containing a palindromic consensus estrogen response element and TGFP3 quite a different nucleotide sequence; only the former was shown to bind the estrogen receptor in gel shift assays. The DNA-binding domain of the estrogen receptor appears not to be required for raloxifene induction of the TGFP3 gene. Since the estrogen receptor does not bind directly to this unusual estrogen response element, an additional DNA-binding protein that tethers estrogen receptor to this enhancer is implied (54). Thus, at least some of the proteins interacting with the ligand-receptor complex at these two promoters would be predicted to be different, to account for the reversed pharmacology displayed by these estrogen receptor ligands at these two genes.
As was mentioned earlier, these findings are also mirrored in tissue-specific differences in the estrogen agonist/antagonist character of these compounds in VollONo.2 viva. Tamoxifen and raloxifene are strong estrogenlike agonists for bone density maintenance in rats and women. They have either some (tamoxifen) or little to no (raloxifene) stimulatory effect on uterine proliferation, yet they are full antagonists of estrogen-stimulated breast cancer cell proliferation and responses such as induction of plasminogen activator activity in breast cancer cells. These observations indicate that these ligands are "selective estrogen receptor modifiers" (27, 30), displaying estrogen agonist or antagonist activity that is dependent on the particular cell and gene endpoint.
Such observations form the basis for efforts currently being directed at the development of tissueselective estrogenlantiestrogen agents with specific profiles optimal for treatment of women with breast cancer and for postmenopausal bone loss (osteoporosis) prevention: no agonism on breast or uterus; estrogen agonism on bone (for good bone maintenance), the cardiovascular system, and some aspects of liver function (such as blood lipid profile). Such compounds would exploit what is now known about the gene-and cell-selective actions of hormonal ligands and the importance of effector site components in a ligand's pharmacological profile (see below). Thus, in some systems, the same ligand working through a single receptor can elicit a different spectrum of responses from different genes in hormone-responsive cells (cf. The development of the concept of "receptors" in classical pharmacology arose from the need to postulate a molecular species that served as the interface between a drug or hormone and the behavioral or physiological responses that it evoked. The original receptor concept, conceived by Ehrlich (55) and Langley (56), formalized by Clark (57) and Gaddum (58), and refined by Ariens and Simonis (59) and Stephenson (60) was basically an operational one. Nevertheless, it permitted the different dose-response relationships displayed by various drugs and hormones to be related to a hypothesized molecular interaction that these species had as ligands for the receptor. The activity of these ligands could then be interpreted in terms of the pharmacological parameters "potency" and "biocharacter": potency, measured as the median efficacy (EC,,, or median inhibition, I&,), was related to the ligand's affinity for the receptor; biocharacter (i.e. agonist vs. antagonist character), estimated by the degree to which this binding resulted in activation of the receptor to elicit a response, was related to the ligand's efficacy or intrinsic activity.
At an operational level, the receptor was considered to represent the interface where the molecular interactions with the ligand ceased and the biological responses began. In such a bipartite model, involving only the ligand and the receptor, the ligand plays a role much like that of an allosteric effector of an enzyme, altering the conformation of the receptor and thereby directly altering its capacity to elicit the response. The conceptual features of such a bipartite scheme are illustrated in Fig. 1 . The key issue is that the receptor itself embodies two functions, the capacity to bind a ligand and the capacity to initiate or effect a response as a direct consequence of that binding. The implications of the bipartite model are subtle but important: since the ligand is controlling the shape and the function of the receptor directly, one can assign to each ligand a unique characteristic potency and biocharacter ( Table 2 ).
The Identification of Steroid Receptors and Their Genomic Action
The preparation of high specific activity radiolabeled steroid hormones more than 3 decades ago led to the identification of specific, high affinity binding proteins in target tissues for steroid hormones (61). Since the binding affinity that these proteins showed for various ligands reflected the biological potency of these ligands quite accurately, the binding proteins were This simple conceptual scheme illustrates how the response to a hormone might be mediated by a bipartite interaction between the hormone, acting as a ligand (L) and a receptor (R). In such a bipartite system, the effect of each hormonal ligand is determined directly by the nature of its interaction with the receptor. Thus, unique potency and biocharacter descriptors can be assigned to each hormone. . The role of these binding proteins as receptors, linking the binding interaction of the steroid with the biochemical response of transcription activation, still appeared to be clear. Nevertheless, it was evident even then that there would be other molecular elements within the cell with which the ligandreceptor complex would need to interact in order for the effect-the transduction of the signal-to continue (67, 68).
In the most recent decade, great strides have been made in determining the structure of these receptors and in elucidating the details of their action. They are multidomain proteins that engage in multiple interactions in the process of eliciting their genetic transcriptional activation or repression responses.
In some cases they interact with themselves as homodimers or with other related receptor partners as heterodimers. At each regulated gene, these receptors may interact with DNA via response elements of varying sequence and distribution, with transcription factors and other components of the general transcription apparatus, and with various other activator and adaptor (co-activator and co-repressor) proteins that are associated with the transcriptional regulation of that particular gene (reviewed in .
This proliferation of molecular constituents that link ligand to response necessitates a reexamination of the simplistic application of the term "receptor" to this intracellular ligand-binding protein.
In fact, in the nuclear receptor signal transduction cascade, it is no longer so clear where the effect of ligand "interaction" ceases and the biological "response" begins, and thereby just what molecular entity or entities linking interaction and response merits the appellation "receptor" in the classical pharmacological sense. The "interaction" by which a ligand effects a response in the steroid hormone system is clearly a multipartite phenomenon, one that is much more complex than the bipartite interaction originally envisioned as simply the binding of a hormone to a receptor protein. The proliferation of such terms and phrases as "cell and promoter context, " "gene-specific effects," "intracellular receptor pharmacology," "post-receptor events in ligand discrimination,"
or the "different biology of various receptor-ligand complexes" to describe steroid hormone pharmacology is a reflection of the inadequacy of the current use of the classical terms "agonist," " antagonist, " and "receptor" to describe the selective action of hormones at the level of the cell and gene.
The Tripartite (Ligand-Receptor-Effector) Systems A tripartite scheme that embodies elements which seem more appropriate to describe steroid hormone molecular pharmacology is shown in Fig. 2 (Table 2) . Whereas the bipartite scheme (Fig. 1) embodied the ligand binding and the response initiation functions in one entity, in the tripartite scheme these functions are assigned to separate entities-ligand binding to the receptor, and response initiation to the effector. Thus, where there were two partners that defined pharmacology, there are now three: the ligand, the receptor, and the effector.
Tripartite or ligand-receptor-effector schemes were proposed some time ago for certain other signal transduction systems, and more recently even for some glucocorticoid receptor-mediated responses (73a), especially those that showed a discordance between ligand potency in response stimulation (measured as the EC,,) and ligand binding to receptor [measured as the dissociation constant (KJ]. For example in the "spare receptor" hypothesis, the effector was proposed as a response-limiting step beyond the receptor that could account for this potency/binding disjunction (74) (75) (76) (77) unusual about the tripartite nature of the nuclear hormone receptor system is that there appears to be an unusual number and variety of effecters; this might well be the hallmark of pleiotropic response systems. The pharmacological implications of the tripartite model are significantly different from the bipartite model. In the bipartite model ( Fig. 1 and Table 2 ), a single interaction, the binding of ligand by receptor, directly regulates receptor function and thereby determines both the potency and the biocharacter of the ligand. By contrast, ligand potency and ligand biocharacter are determined through two different interactions in the tripartite scheme ( Fig. 2 and Table 2 ). In the first interaction, ligand binds to receptor to form a complex, and the affinity of this binding is a principal determinant of ligand potency. However, this ligandreceptor interaction alone does not control the response and therefore is not a direct determinant of ligand biocharacter.
The pharmacological nature of the ligand, its biocharacter and its potency, is only fully established through the second interaction. This coupling, which occurs between the ligand-receptor complex and the third partner, the effector, is an interaction that has both an affinity and an efficacy dimension.
The Nature of Effecters for Nuclear Receptors
In the nuclear hormone receptor systems, the effector site represents the aggregate of all the other components with which the ligand-receptor complex interacts at each regulated gene. Thus, the effector is obviously complex. It is made up of elements common to all genes, as well as elements unique to each cell and to each gene, even in systems like the estrogen receptor where only a single receptor exists. The nuclear components that define effector-site selectivity are not well understood at present. Nevertheless, they may be grouped into several classes, three of which are illustrated in Fig. 2 .
In most cases, the coupling between the receptor and effector involves direct interaction with DNA through hormone response elements, which at various genes may be consensus, nonconsensus, single, multiple, half-sites, etc.; DNA sequences flanking the response elements, which are known to affect receptor binding affinity, also differ in various responsive genes. For the most part, sequences that bind receptors with high affinity act as tethering sites for these potent gene activators. In certain instances such as the proliferin gene, upstream binding to a specific sequence appears to favor a conformationally inactive form of the glucocorticoid receptor and may be operationally defined as a negative glucocorticoid response element 630).
After binding to their cognate response elements, a number of receptors appear to touch the general transcription factor complex (GTFs) located at the TATA box (cf. Fig. 2 , effector system 1) (81-83). Although TFIID may be a target for certain receptors, the preferred partner of progesterone, estrogen, thyroid hormone, vitamin D, receptors, and COUP-TF often appears to be TFIIB, a rate-limiting component whose presence appears requisite for drawing RNA polymerase (and TFIIF) to the promoter (84). At this level, both positive and negative associations have been predicted for receptors with TFIIB. For example, unoccupied thyroid hormone receptor touches TFIIB at two distinct regions; one of these interactions has been hypothesized to be repressive, to explain the well described silencing activity of ligand-free thyroid hormone receptor at certain genes (82). Thyroid hormone binding to thyroid hormone receptor inhibits this repressive interaction.
Nevertheless, effector site interactions appear to be of even greater complexity.
Experimental evidence has predicted the existence of adaptor proteins that may act as either coactivators (85, 86) or corepressors for nuclear receptors (cf. Fig.  2, effector system 2) . In transfected cells, the ability of activated estrogen receptor to suppress or "squelch" the transcriptional capacity of activated progesterone receptor has been interpreted to result from their competitive interactions with limiting concentrations of a putative cellular coactivator (87-89). Recently, this hypothesis has been substantiated by the identification and cloning of a general steroid receptor coactivator (SRC-I), which fulfills many of the criteria that have been preassigned to such a molecule, i.e. it enhances ligand-induced gene activity (up to IO-fold) without altering basal transcription levels, and it can reverse interreceptor squelching when transfected into a cell with two active receptors (90). SRC-1 appears to exist in two isoforms and its mRNA is present in all cells. It specifically interacts with the C-terminal activation domain (AF-2) of receptors in a ligand-dependent manner but functions with all steroid/thyroid/retinoic acid receptors tested to date. This coactivator is inactive with receptors bound to pure antagonists but has been shown recently to enhance mixed agonistlantagonist activation of ER as well as ligand-independent activation of receptor by dopaminergic agonists and growth factors. Other potential adaptor proteins that interact with steroid receptors in a ligand-regulated manner, termed receptor-associated proteins (RAPS) or receptor-interacting proteins (RIPS), have been identified, although none have been proven yet to function as transcriptional coactivators. Cells with an abundance of coactivator should have a more pronounced response to a limiting concentration of receptor. It is clear that receptor-coactivator interactions are an important part of the tripartite response system at the gene level and can play a major role in quantitative aspects of cell response.
Elucidation of the molecular interactions of SRC-1 and other coactivators with receptor should advance our understanding of the mechanism of antagonist action. Previous experimental evidence has indicated that agonist-and antagonist-bound receptors exist in distinct conformations (91, 92). Interestingly, agonistbound receptor binds efficiently to coactivator in vitro and in vivo, but the antagonist-bound receptor does not bind coactivator. Such differential interactions are illustrated by the varying activities postulated for the different ligand receptor complexes with effector system 2 (Fig. 2, bottom) and suggest that antagonist action has its origin at two levels, that of ligand-induced receptor conformation and that of receptoreffector interaction at the genetic level (see below). In such a scheme, antagonist-bound receptor occupies available hormone response elements in the cell, but its conformation does not allow productive interactions with coactivators or the general transcription factor apparatus at the core promoter (TATA box).
Recent data suggesting the existence of a corepressor(s) for the thyroid hormone receptor (and retinoic acid receptor) add an additional twist (93, 94). Unoccupied nuclear thyroid hormone receptor has been reported to silence target gene activity (95, 96). Presentation of thyroid hormone ('T,) reverses silencing and produces a stimulation of transcription. It has been proposed, using reverse squelching experiments to relieve silencing, that a soluble corepressor in target cells binds to unoccupied but not ligand-bound receptor, thus aiding in the thyroid hormone receptor-induced repression of basal transcription at select target genes (93). Recently, two "corepressor" molecules appear to have been cloned in their entirety and seem to fulfill the expected criteria, i.e. selective silencing, which is dependent on unoccupied thyroid hormone receptor or retinoic acid receptor (97, 98 Fig. 2, effector system 3) . Likewise, in some target genes with unusual estrogen-inducible enhancers, such as c-myc (log), creatine kinase (1 lo), cathepsin D (11 I), and the protooncogene c-jun (112) Finally, it is worth noting that chromatin structure of genes in their native context provides a significant barrier for receptor to overcome in transcriptional regulation (40, 72, 116, 117) . Nucleosomal repression of gene activation must be reversed by receptors, and selected nuclear helper proteins (e.g. SWI, SWE, SNF, Sin, etc.) may play important roles in the chromatin remodeling that appears to coincide with induction of transcription.
In any event, it is certain that a diverse spectrum of interactions can occur at an effector site and that this complexity may represent a mechanism whereby promoter context and cell specificity of response can be generated.
Pharmacology
in Tripartite (Ligand-ReceptorEffector) Systems
In Fig. 2 , we have laid out three tripartite schemes to illustrate the types of molecular interactions that may be operating in the activation of gene transcription by nuclear hormone receptors. Through this figure, we also have attempted to represent the combinatorial complexity that can arise as a result of the second interaction, between the ligand receptor complex and the effector. The interactions at the top of Fig. 2 illustrate the optimal interaction that might occur between three distinct effector systems and three different ligand receptor complexes, each formed from the same receptor with three different types of ligands; shown is the fact that each ligand-receptor complex has a distinct conformation.
At the bottom of Fig. 2 , we attempt to show the consequence-in terms of signal transduction-of the distinct interaction that each of these ligand-receptor complexes might have with all three of the effector systems. While this illustration is obviously limited and simplified (see previous section "The Nature of Effecters for Nuclear Receptors" and see below), it is meant to capture the conceptual basis of pharmacology in a tripartite receptor system, especially the fact that response diversity can be generated at the level of the effector. In addition to the three scenarios shown in Fig. 2 , diversity can also be generated further by differences in the nature of the hormone response element, the influence of neighboring DNA-binding sites for other nuclear factors, as well as the nature of the promoter and chromatin state/ conformation.
The transcription activation functions ascribed to different regions of nuclear hormone receptors (AF-1 and 2, or ~1-74) can be thought of as sites through which the receptor has the potential for interaction with these various effecters (70, 72, 73) . However, the degree to which a particular ligand may engender the receptor to operate through these different activation function sites depends on the nature of the specific effector system with which the ligand-receptor complex interacts. Again, this is dependent on the cell-and promoter-specific factors and the response elements that constitute the effector. In cotransfection systems, mutant receptors can be used to amplify the varied effects of different ligands in their interaction with specific effector sites (5, 41, 43, 118-l 23) . This approach has assisted in the identification of ligands with specific desired biocharacter, such as ligands for the estrogen receptor that have the proper spectrum of agonist/antagonist activity needed for hormone replacement therapy (43).
In tripartite receptor pharmacology, it is useful to consider that the potency of a particular ligand is determined principally through the first interaction (ligand and receptor binding), whereas its biocharacter (Le. agonist-antagonist balance) is determined principally through the second interaction (receptor-effector coupling). This may prove to be an oversimplification, as there are known exceptions.
In model transcription systems in yeast, certain receptor-modulatory proteins (SSNG-TUPI) have been shown to alter ligand potency (EC,,) of both estrogens and progestins by several orders of magnitude, not by a perturbation of ligand receptor binding, but by alteration of receptoreffector coupling that is interpreted as a modification of AF-I activity. In this system, these adaptor proteins also alter the biocharacter of antiestrogens without changing ligand affinity (89). Related studies have defined a glucocorticoid modulatory element in the tyrosine amino transferase gene, and associated transactivating factors, that alter ligand potency and biocharacter (123). Conversely, it is possible that variations in response element sequence that affect receptor-effector coupling might also alter the conformation of the receptor in a manner that would change ligand affinity. Further investigation of ligand-receptor binding and receptor-effector coupling in carefully controlled systems will be required to fully elucidate the relative role that each interaction plays in establishing pharmacological potency and biocharacter. Regardless of these details, however, in a tripartite receptor system, the pharmacological parameters of potency and biocharacter are not unique characteristics of a ligand; they can be assigned to a ligand only when reference is made to a specific response or its associated effector (Table 2) .
CONSEQUENCES AND EXPECTATIONS
A prerequisite for receptor pharmacology, be it bipartite or tripartite, is that ligand binding effects some conformational change in the receptor that initiates the response (directly-bipartite) or the potential for response (through coupling with effecters-tripartite).
It is clear that the binding of a hormone ligand by its nuclear receptor results in significant conformational changes in the receptor. This has been evident for some time through indirect studies that have noted alterations in thermal stability, antibody binding, heat shock protein dissociation, hydrophobicity, DNA binding, and protease sensitivity upon ligand binding. More recently, crystallographic evidence (124-l 26) has shown that the small nuclear receptor ligands are almost completely surrounded by protein in their complexes with receptor. Moreover, within this complex there appear to be intimate and detailed contacts between protein and ligand over the whole ligand surface so that, of necessity, the conformation of a steroidnuclear receptor complex must reflect the shape and structure of its ligand. Thus, the affinity and efficacy with which these conformationally diverse ligand-receptor complexes interact with the various effector sites involved in the transcriptional regulation of different genes reflect the structure of the receptor complex in its specific ligand-induced conformation. What are the implications of this ligand-determined conformation of the nuclear hormone receptors?
First, it is not surprising that in the nuclear hormone receptor system, ligands of different structure operating through the same receptor can show distinct celland gene-specific effects. One should expect that the same receptor, bound with ligands of different structure, gives rise to complexes of different conformation. Such conformationally different ligand-receptor complexes have the potential for different coupling with the spectrum of effector sites that are present in each target cell and that embody all the cell-and genespecific factors that enable individual genes to be differentially regulated by different ligands. At the moment, the number of genes whose expression is known to be regulated as a primary response to steroid hormones is rather limited. As more are identified, it is likely that the diversity of response to ligands that is possible with this tripartite receptor system will become even more evident.
Second, in contrast to allosteric effector ligand,s in enzyme systems and ion channels that bind rapidly to preformed regulatory sites and act like switches controlling the conformation between two states, active and inactive (conformation selection) (127), one should expect the hormonal ligand to affect the conformation of the receptor in more of a progressive or continuum fashion. The rate at which ligands associate with nuclear receptors is slow, far below diffusion control, which characterizes most small molecule-protein interactions. This suggested that the receptor undergoes a substantial conformational reorganization upon binding the ligand. Furthermore, since many unliganded receptors are associated with certain heat shock proteins, the sequences that constitute the ligandbinding pocket were thought to be somewhat disordered in the absence of ligand. Both of these expectations have been confirmed by recent X-ray crystal structures (124) (125) (126) . Thus, the formation of the ligand-receptor complex in the nuclear hormone receptor system is an excellent example of an induced fit (128), conformation induction (127), or macromolecular perturbation (129), with the receptor conforming to the shape of the ligand (and the ligand, if flexible, having its conformation altered by binding to the receptor as well) (125, 126) .
Finally, while structural elucidation methods will soon give us high resolution models for many nuclear receptors binding ligands of varying structure, the impact of this structural information on our understanding of steroid hormone molecular pharmacology, though very useful, will still be limited. The picture will be complete only when the details governing the COUpling of these ligand-receptor complexes with the 128 
